Fidelity Investments’s Context Therapeutics CNTX Stock Holding History

Fidelity Investments’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44K	Buy	+2,594	New	+$5.26K	﹤0.01%	5195

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments's CNTX Position: Q2 2026 in Review

Fidelity Investments opened a new position in Context Therapeutics (CNTX) in Q2 2026: 2,594 shares worth $1.44K. The stake represents ﹤0.01% of the portfolio and ranks #5195 among its holdings.

79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Fidelity Investments held 2,594 shares of Context Therapeutics worth $1.44K as of Q2 2026.
Context Therapeutics was a new Fidelity Investments position in Q2 2026.
Context Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5195 holding.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.